Your browser doesn't support javascript.
loading
Identification of MYC as an antinecroptotic protein that stifles RIPK1-RIPK3 complex formation.
Seong, Daehyeon; Jeong, Manhyung; Seo, Jinho; Lee, Ji-Yoon; Hwang, Chi Hyun; Shin, Ho-Chul; Shin, Jeong Yoon; Nam, Young Woo; Jo, Jeong Yeon; Lee, Haeseung; Kim, Hye-Jung; Kim, Hwa-Ryeon; Oh, Ji Hoon; Ha, Sang-Jun; Kim, Seung Jun; Roe, Jae-Seok; Kim, Wankyu; Cheong, June-Won; Bae, Kwang-Hee; Lee, Sang Chul; Oberst, Andrew; Vandenabeele, Peter; Shin, Dong Hoon; Lee, Eun-Woo; Song, Jaewhan.
Afiliación
  • Seong D; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Jeong M; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Seo J; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Lee JY; Environmental Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology, 34141 Daejeon, Republic of Korea.
  • Hwang CH; Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, 34141 Daejeon, Republic of Korea.
  • Shin HC; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Shin JY; Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, 34141 Daejeon, Republic of Korea.
  • Nam YW; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Jo JY; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Lee H; Research Institute, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, 10408 Goyang, Republic of Korea.
  • Kim HJ; Department of Life Sciences, Ewha Research Center for Systems Biology, Ewha Womans University, 03760 Seoul, Republic of Korea.
  • Kim HR; New Drug Development Center, Korea Biotechnology Industry Organization Osong Medical Innovation Foundation, 28160 Cheongju-si, Republic of Korea.
  • Oh JH; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Ha SJ; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Kim SJ; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Roe JS; Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, 34141 Daejeon, Republic of Korea.
  • Kim W; Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, 120-749 Seoul, Republic of Korea.
  • Cheong JW; Department of Life Sciences, Ewha Research Center for Systems Biology, Ewha Womans University, 03760 Seoul, Republic of Korea.
  • Bae KH; Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 03722 Seoul, Republic of Korea.
  • Lee SC; Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, 34141 Daejeon, Republic of Korea.
  • Oberst A; Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology, 34141 Daejeon, Republic of Korea.
  • Vandenabeele P; Department of Immunology, University of Washington, Seattle, WA 98109.
  • Shin DH; Vlaams Instituut voor Biotechnologie-University of Ghent Center for Inflammation Research, Vlaams Instituut voor Biotechnolgie, 9052 Ghent, Belgium.
  • Lee EW; Department of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium.
  • Song J; Research Institute, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, 10408 Goyang, Republic of Korea.
Proc Natl Acad Sci U S A ; 117(33): 19982-19993, 2020 08 18.
Article en En | MEDLINE | ID: mdl-32753382
The underlying mechanism of necroptosis in relation to cancer is still unclear. Here, MYC, a potent oncogene, is an antinecroptotic factor that directly suppresses the formation of the RIPK1-RIPK3 complex. Gene set enrichment analyses reveal that the MYC pathway is the most prominently down-regulated signaling pathway during necroptosis. Depletion or deletion of MYC promotes the RIPK1-RIPK3 interaction, thereby stabilizing the RIPK1 and RIPK3 proteins and facilitating necroptosis. Interestingly, MYC binds to RIPK3 in the cytoplasm and inhibits the interaction between RIPK1 and RIPK3 in vitro. Furthermore, MYC-nick, a truncated form that is mainly localized in the cytoplasm, prevented TNF-induced necroptosis. Finally, down-regulation of MYC enhances necroptosis in leukemia cells and suppresses tumor growth in a xenograft model upon treatment with birinapant and emricasan. MYC-mediated suppression of necroptosis is a mechanism of necroptosis resistance in cancer, and approaches targeting MYC to induce necroptosis represent an attractive therapeutic strategy for cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia / Proteínas Proto-Oncogénicas c-myc / Proteína Serina-Treonina Quinasas de Interacción con Receptores Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia / Proteínas Proto-Oncogénicas c-myc / Proteína Serina-Treonina Quinasas de Interacción con Receptores Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos